Making the undruggable druggable
Unlocking challenging drug targets for the development of next-generation therapeutics
Selected Collaborations
It all starts with the drug target.
The majority of drug targets are so-called membrane proteins, and these are inherently unstable and challenging to investigate. Or so they were, until now.
Our proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies or small molecule drugs. Through our in-house and partnered pipelines, we drive the discovery of novel drugs.
Pushing drug development forward together
We work with top-tier pharma and biotech partners to unlock drug targets for drug development programs.
Pipeline
We are driving forward drug development in our partnered as well as internal pipelines.
News
New study with Salipro® - Reprogramming Cancer Cells to Fight Themselves
2025-07-08
We are excited to share a new study published in Cell Discovery that opens new avenues in cancer treatment by reprogramming cancer metabolism to enhance immune responses and fight tumors.
Targeting complex membrane protein assemblies - like the Basigin-MCT transporter - has long been a major challenge in oncology. Understanding how to modulate their function is critical for creating effective new therapies. The study introduces a novel antibody that reprograms the basigin protein, transforming it from a tumor enabler into a suppressor of the cancer’s metabolic fuel supply.
With the Salipro® platform, the researchers achieved high-resolution cryo-EM and molecular dynamics simulations, revealing the precise mechanism by which the antibody modulates MCT1 and MCT4 transporters.
This structural insight provides a detailed map of the antibody-protein interaction, paving the way for more precise medicines with potentially fewer side effects.
Congratulations to the teams for their contribution to the fields of cancer biology and structural immunology!
Find the full study:
H. Zhang, et al., A basigin antibody modulates MCTs to impact tumor metabolism and immunity. Cell Discovery, (2025).
New Publication- Unraveling the Code of Brain Ion Channels with Salipro®
2025-07-03
A new exciting study published in the British Journal of Pharmacology sheds new light on the modulation of pentameric ligand-gated ion channels (pLGICs), a key target for many therapeutics.
Understanding how these molecules modulate the function of pLGICs is vital for developing novel drugs for a range of neurological disorders. In this work, the Salipro® platform enabled the researcher to capture a detailed view of a pentameric ligand-gated ion channel (sTeLIC) interacting with stimulant-like molecules.
This new research opens up new avenues for the design of next-generation drugs targeting these important receptors.
Congratulations to the teams at Stockholm University, KTH Royal Institute of Technology, and Institut Pasteur for their significant contribution to the field of pharmacology and structural biology!
Find the full study:
E. Karlsson, et al., Vestibular modulation by stimulant derivatives in a pentameric ligand-gated ion channel. British Journal of Pharmacology, 182(12), 2790–2802 (2025).
Salipro to join the Nordic Health Summit Japan 2025
2025-06-13
Salipro Biotech will join the Nordic Health Summit Japan 2025, taking place in Tokyo on June 27 (virtual)!
Lorena Galán and Peter Jahnmatz will be online to connect and discuss the advantages of the Salipro® technology with pharma leaders and innovators in Japan.
Book a meeting with us via the partnering platform to learn more about the latest advancements of Salipro® and explore collaboration opportunities in drug discovery targeting membrane proteins.
We look forward to fruitful meetings and engaging with the Japanese pharma ecosystem!